Population pharmacokinetic/pharmacodynamic modeling of NH600001 reveals age-related differences in sedation response and supports individualized dosing in elderly patients.

Background

NH600001 is a novel intravenous anesthetic developed as a safer alternative to etomidate. Its pharmacokinetic/pharmacodynamic (PK/PD) profile and optimal dosing in elderly patients remain insufficiently characterized. This study aimed to develop a population PK/PD model of NH600001 and evaluate age‑related differences in disposition and sedation response. RESEARCH

Design

AND

Methods

Data from seven clinical studies involving 457 subjects were pooled. Plasma concentrations, bispectral index (BIS), and modified observer's assessment of alertness/sedation (MOAA/S) were analyzed using nonlinear mixed‑effects modeling. A three‑compartment model with allometric scaling and effect‑compartment PD models were developed, followed by covariate analysis, bootstrap validation, visual predictive checks, exposure-response evaluation, and clinical simulations.

Results

Age category, concomitant alfentanil, population category, and sex significantly affected PK parameters. BIS and MOAA/S models adequately described NH600001‑induced sedation. Simulations showed that elderly subjects achieved BIS ≤ 60 more rapidly and maintained sedation longer than non‑elderly subjects at identical doses, with flat exposure-response relationships for recovery and safety endpoints.

Conclusions

The PopPK/PD model characterizes age‑related variability in NH600001 and supports age‑tailored dosing strategies for precision anesthesia in elderly patients.